CL2022003056A1 - Polymorphic forms of (r)-oxybutynin hydrochloride - Google Patents

Polymorphic forms of (r)-oxybutynin hydrochloride

Info

Publication number
CL2022003056A1
CL2022003056A1 CL2022003056A CL2022003056A CL2022003056A1 CL 2022003056 A1 CL2022003056 A1 CL 2022003056A1 CL 2022003056 A CL2022003056 A CL 2022003056A CL 2022003056 A CL2022003056 A CL 2022003056A CL 2022003056 A1 CL2022003056 A1 CL 2022003056A1
Authority
CL
Chile
Prior art keywords
polymorphic forms
oxybutynin hydrochloride
oxybutynin
forms
hydrochloride
Prior art date
Application number
CL2022003056A
Other languages
Spanish (es)
Inventor
Molnar Dennis
Johnston Sean
Original Assignee
Apnimed Inc Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apnimed Inc Delaware filed Critical Apnimed Inc Delaware
Publication of CL2022003056A1 publication Critical patent/CL2022003056A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/20—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Polymorphic forms of (R)-oxybutynin HC1, including three crystalline forms, are prepared and characterized. Uses of the various polymorphic forms of (R)-oxybutynin HC1 for Obstructive Sleep Apnea (OS A) treatment are also disclosed.Polymorphic forms of (R)-oxybutynin HC1, including three crystalline forms, are prepared and characterized. Uses of the various polymorphic forms of (R)-oxybutynin HC1 for Obstructive Sleep Apnea (OS A) treatment are also disclosed.

CL2022003056A 2020-05-05 2022-11-04 Polymorphic forms of (r)-oxybutynin hydrochloride CL2022003056A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063020301P 2020-05-05 2020-05-05
US202163136691P 2021-01-13 2021-01-13

Publications (1)

Publication Number Publication Date
CL2022003056A1 true CL2022003056A1 (en) 2023-06-30

Family

ID=76060009

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022003056A CL2022003056A1 (en) 2020-05-05 2022-11-04 Polymorphic forms of (r)-oxybutynin hydrochloride

Country Status (3)

Country Link
CL (1) CL2022003056A1 (en)
TW (1) TW202208325A (en)
WO (1) WO2021226020A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023118102A1 (en) * 2021-12-22 2023-06-29 Bayer Aktiengesellschaft Combination of a task1/3 channel blocker with a muscarinic receptor antagonist for the treatment of sleep apnea

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US6562368B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
US20110087042A1 (en) * 2008-02-04 2011-04-14 Matrix Laboratories Limited Crystalline oxybutynin and process for preparing the same

Also Published As

Publication number Publication date
WO2021226020A1 (en) 2021-11-11
TW202208325A (en) 2022-03-01

Similar Documents

Publication Publication Date Title
PH12019500296A1 (en) Amino pyrimidine ssao inhibitors
NO20075086L (en) Treatment of Parkinson's disease, obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamine histamine H3 receptor ligands
CY1117952T1 (en) ROOT INSULTS
NO20052591D0 (en) Pyridopyrolizine and pyridoindolizine derivatives
NO20082112L (en) 3-Amino-2-arylpropylazaindoles and their use
CL2022003056A1 (en) Polymorphic forms of (r)-oxybutynin hydrochloride
MX2010002081A (en) Processes for the preparation of crystalline forms a, b and pure crystalline form a of erlotinib hcl.
NO20082096L (en) Azaindole-2-karboksamidderivativer
EA201200429A1 (en) DERIVATIVES OF CYCLOPROPILAMIDE
CY1112645T1 (en) POLYMORPH B OF N- (2-AMINOFYNYL) -4- [N- (PYRIDIN-3-YL) Methoxycarbonyl-aminomethyl] benzamide (MS-275)
DE602006006546D1 (en) 9A-CARBAMOYL AND THIOCARBAMOYLAZALIDES WITH ANTIMALARIA EFFECT
HK1145834A1 (en) Phenylpyrazole derivatives
JOP20210059A1 (en) ?2-Adrenoceptor subtype C (alpha-2C) antagonists for the treatment of sleep apnea
DK1368019T4 (en) esmolol
NO20054721L (en) Substituted aniline derivatives
CR20220617A (en) Polymorphic forms of (r)-oxybutynin hydrochloride
ATE418553T1 (en) HISTAMINE H3 RECEPTOR INHIBITORS, THEIR PRODUCTION AND THERAPEUTIC APPLICATIONS
MX2018015508A (en) Pharmaceutical salts of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy- 5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acryla mide and crystalline forms thereof.
AU2022298632A1 (en) Methods for treating obstructive sleep apnea
CY1111430T1 (en) USE OF AGOMELATIN FOR TAKING MEDICINALS FOR SMITH MAGENIS Syndrome Therapy
NO20014475L (en) Method of treating sleep apnea
NO20090421L (en) Arylpiperazine derivatives and their use
SE0402591D0 (en) Novel use
NO20063952L (en) Chemokine-inhibiting piperazine derivatives and their use to treat multiple myeloma
ATE295845T1 (en) PRUCALOPRIDE-N-OXIDE